Report on recent progress of myelodysplastic syndrome in the 54th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2013.01.007
- VernacularTitle:骨髓增生异常综合征最新研究进展:第54届美国血液学会年会报道
- Author:
Ping LIU
;
Baoan CHEN
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Mechanism;
Treatment;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(1):17-18,20
- CountryChina
- Language:Chinese
-
Abstract:
The myelodysplastic syndromes (MDS) are a group of clonal disorders of the hematopoietic stem/progenitor cells characterized by the presence of ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (AML).In the 54th ASH annual meeting,lots of new discoveries about the molecular mechanisms (such as mutations in ASXL1 and Dido1) behind MDS and the relationship between the mechanisms and the clinical outcomes were introduced.On therapy,novel agents based on the molecular mechanisms occured extending survival.Haematopoietic stem cell transplantation (HSCT) remains the only curative therapy,there' re also many developments in HSCT reported in the meeting.
